Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Sanomab Announces Exclusive Evaluation License Agreement for Pancreatic Cancer Monoclonal AntibodySanomab annouces an exclusive evaluation license agreement with the National Cancer Institute (NCI) for the rights to a monoclonal antibody. Sanomab will develop the novel human therapeutic antibody for use in the treatment of pancreatic cancer.
By: Sanomab Ltd "This agreement represents Sanomab’s first milestone in our efforts to accelerate the development of new antibody therapies that incorporate the latest scientific advances for rapid clinical evaluation,” After years of research studying tumour cell biology, researchers at the NCI discovered overexpressed cell surface molecules on the surface of a number of cancers, including pancreatic cancer cells. In this instance, NCI researchers have identified a monoclonal antibody that is capable of binding to cell surface antigen that result in Antibody Dependant Cellular Cytotoxicity (ADCC) killing of the cancer cells. Sanomab will be working with industry partners to further develop this technology. Guided by novel companion diagnostics and advanced medical devices, these will greatly improve the odds of developing a novel therapy that can kill the cancer cells. Promising data should ultimately result in the advancement of the mAb into preclinical and clinical evaluation. Pancreatic cancer affects both men and women and has one of the highest rates of mortality for all cancers. Over 8,000 cases were diagnosed in the UK in 2009. The proportion of people surviving pancreatic cancer is extremely low. The length of time between diagnosis and death is typically short, at usually less than six months. Around only 16% of those diagnosed with the disease survive over one year. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|